 | • レポートコード：MRC2Q12-16754 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、126ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約の売上および2028年までの予測に焦点を当てています。 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約のグローバル主要企業には、1ST Biotherapeutics、3B Pharmaceuticals、3D-Micromac、3DMed、3D Systems、10X Genomics、A*STAR Agency for Science、Technology and Research、A*STAR Institute of Microelectronics (IME)、A2A Pharmaceuticals、Abbvie、AbCellera、ABL Bio、Abpro、Academy of Military Medical Sciences (China)、Accellix、Accord Healthcare、AccuGenomics、ACEA Biosciences、AC Immune、Acoustic MedSystems、Adaptimmune、Aduro BioTech、Advaxis、Adventus Ventures、Aerolaseなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約市場は、タイプとアプリケーションによって区分されます。世界の製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 資産購入、譲渡、共同開発、共同マーケティング、共同プロモーション、共同研究開発、受託サービス、CRADA、クロスライセンス、その他 【アプリケーション別セグメント】 産業分野、治療分野、技術タイプ、ディールコンポーネント、金融用語、開発段階、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約製品概要 - タイプ別市場（資産購入、譲渡、共同開発、共同マーケティング、共同プロモーション、共同研究開発、受託サービス、CRADA、クロスライセンス、その他） - アプリケーション別市場（産業分野、治療分野、技術タイプ、ディールコンポーネント、金融用語、開発段階、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約販売量予測2017-2028 - 世界の製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約売上予測2017-2028 - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約の地域別販売量 - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約販売量 - 主要メーカー別製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約売上 - 主要メーカー別製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（資産購入、譲渡、共同開発、共同マーケティング、共同プロモーション、共同研究開発、受託サービス、CRADA、クロスライセンス、その他） - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約のタイプ別販売量 - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約のタイプ別売上 - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約のタイプ別価格 ・アプリケーション別市場規模（産業分野、治療分野、技術タイプ、ディールコンポーネント、金融用語、開発段階、その他） - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約のアプリケーション別販売量 - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約のアプリケーション別売上 - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約のアプリケーション別価格 ・北米市場 - 北米の製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約市場規模（タイプ別、アプリケーション別） - 主要国別の製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約市場規模（タイプ別、アプリケーション別） - 主要国別の製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約市場規模（タイプ別、アプリケーション別） - 主要国別の製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約市場規模（タイプ別、アプリケーション別） - 主要国別の製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約市場規模（タイプ別、アプリケーション別） - 主要国別の製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約市場規模（トルコ、サウジアラビア） ・企業情報 1ST Biotherapeutics、3B Pharmaceuticals、3D-Micromac、3DMed、3D Systems、10X Genomics、A*STAR Agency for Science、Technology and Research、A*STAR Institute of Microelectronics (IME)、A2A Pharmaceuticals、Abbvie、AbCellera、ABL Bio、Abpro、Academy of Military Medical Sciences (China)、Accellix、Accord Healthcare、AccuGenomics、ACEA Biosciences、AC Immune、Acoustic MedSystems、Adaptimmune、Aduro BioTech、Advaxis、Adventus Ventures、Aerolase ・産業チェーン及び販売チャネル分析 - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約の産業チェーン分析 - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約の原材料 - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約の生産プロセス - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約の販売及びマーケティング - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約の産業動向 - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約のマーケットドライバー - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約の課題 - 製薬・バイオテクノロジー・診断用共同開発パートナリング条件＆契約の阻害要因 ・主な調査結果 |
Co-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics include 1ST Biotherapeutics, 3B Pharmaceuticals, 3D-Micromac, 3DMed, 3D Systems, 10X Genomics, A*STAR Agency for Science, Technology and Research and A*STAR Institute of Microelectronics (IME), etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market. Further, it explains the major drivers and regional dynamics of the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
1ST Biotherapeutics
3B Pharmaceuticals
3D-Micromac
3DMed
3D Systems
10X Genomics
A*STAR Agency for Science
Technology and Research
A*STAR Institute of Microelectronics (IME)
A2A Pharmaceuticals
Abbvie
AbCellera
ABL Bio
Abpro
Academy of Military Medical Sciences (China)
Accellix
Accord Healthcare
AccuGenomics
ACEA Biosciences
AC Immune
Acoustic MedSystems
Adaptimmune
Aduro BioTech
Advaxis
Adventus Ventures
Aerolase
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Segment by Type
Asset purchase
Assignment
Co-development
Co-market
Co-promotion
Collaborative R&D
Contract service
CRADA
Cross-licensing
Others
Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Segment by Application
Industry sector
Therapy areas
Technology type
Deal components
Financial terms
Stage of development
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including 1ST Biotherapeutics, 3B Pharmaceuticals, 3D-Micromac, 3DMed, 3D Systems, 10X Genomics, A*STAR Agency for Science, Technology and Research and A*STAR Institute of Microelectronics (IME), etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Asset purchase
1.2.3 Assignment
1.2.4 Co-development
1.2.5 Co-market
1.2.6 Co-promotion
1.2.7 Collaborative R&D
1.2.8 Contract service
1.2.9 CRADA
1.2.10 Cross-licensing
1.2.11 Others
1.3 Market by Application
1.3.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Industry sector
1.3.3 Therapy areas
1.3.4 Technology type
1.3.5 Deal components
1.3.6 Financial terms
1.3.7 Stage of development
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Perspective (2017-2028)
2.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Growth Trends by Region
2.2.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Region (2017-2022)
2.2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Region (2023-2028)
2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Dynamics
2.3.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industry Trends
2.3.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Drivers
2.3.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Challenges
2.3.4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players by Revenue
3.1.1 Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players by Revenue (2017-2022)
3.1.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Players (2017-2022)
3.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue
3.4 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio
3.4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in 2021
3.5 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Key Players Head office and Area Served
3.6 Key Players Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Solution and Service
3.7 Date of Enter into Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Type
4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Type (2017-2022)
4.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Type (2023-2028)
5 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Application
5.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Application (2017-2022)
5.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028)
6.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
6.2.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2017-2022)
6.2.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2023-2028)
6.2.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2017-2028)
6.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
6.3.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2017-2022)
6.3.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2023-2028)
6.3.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2017-2028)
6.4 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country
6.4.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2017-2022)
6.4.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028)
7.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
7.2.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2017-2022)
7.2.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2023-2028)
7.2.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2017-2028)
7.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
7.3.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2017-2022)
7.3.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2023-2028)
7.3.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2017-2028)
7.4 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country
7.4.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2017-2022)
7.4.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028)
8.2 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
8.2.1 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2017-2028)
8.3 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
8.3.1 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2017-2028)
8.4 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region
8.4.1 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028)
9.2 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
9.2.1 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2017-2022)
9.2.2 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2023-2028)
9.2.3 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2017-2028)
9.3 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
9.3.1 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2017-2022)
9.3.2 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2023-2028)
9.3.3 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2017-2028)
9.4 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country
9.4.1 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2017-2022)
9.4.2 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2017-2028)
10.2 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
10.2.1 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type (2017-2028)
10.3 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
10.3.1 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application (2017-2028)
10.4 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country
10.4.1 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 1ST Biotherapeutics
11.1.1 1ST Biotherapeutics Company Details
11.1.2 1ST Biotherapeutics Business Overview
11.1.3 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.1.4 1ST Biotherapeutics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.1.5 1ST Biotherapeutics Recent Developments
11.2 3B Pharmaceuticals
11.2.1 3B Pharmaceuticals Company Details
11.2.2 3B Pharmaceuticals Business Overview
11.2.3 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.2.4 3B Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.2.5 3B Pharmaceuticals Recent Developments
11.3 3D-Micromac
11.3.1 3D-Micromac Company Details
11.3.2 3D-Micromac Business Overview
11.3.3 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.3.4 3D-Micromac Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.3.5 3D-Micromac Recent Developments
11.4 3DMed
11.4.1 3DMed Company Details
11.4.2 3DMed Business Overview
11.4.3 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.4.4 3DMed Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.4.5 3DMed Recent Developments
11.5 3D Systems
11.5.1 3D Systems Company Details
11.5.2 3D Systems Business Overview
11.5.3 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.5.4 3D Systems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.5.5 3D Systems Recent Developments
11.6 10X Genomics
11.6.1 10X Genomics Company Details
11.6.2 10X Genomics Business Overview
11.6.3 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.6.4 10X Genomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.6.5 10X Genomics Recent Developments
11.7 A*STAR Agency for Science
11.7.1 A*STAR Agency for Science Company Details
11.7.2 A*STAR Agency for Science Business Overview
11.7.3 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.7.4 A*STAR Agency for Science Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.7.5 A*STAR Agency for Science Recent Developments
11.8 Technology and Research
11.8.1 Technology and Research Company Details
11.8.2 Technology and Research Business Overview
11.8.3 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.8.4 Technology and Research Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.8.5 Technology and Research Recent Developments
11.9 A*STAR Institute of Microelectronics (IME)
11.9.1 A*STAR Institute of Microelectronics (IME) Company Details
11.9.2 A*STAR Institute of Microelectronics (IME) Business Overview
11.9.3 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.9.4 A*STAR Institute of Microelectronics (IME) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.9.5 A*STAR Institute of Microelectronics (IME) Recent Developments
11.10 A2A Pharmaceuticals
11.10.1 A2A Pharmaceuticals Company Details
11.10.2 A2A Pharmaceuticals Business Overview
11.10.3 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.10.4 A2A Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.10.5 A2A Pharmaceuticals Recent Developments
11.11 Abbvie
11.11.1 Abbvie Company Details
11.11.2 Abbvie Business Overview
11.11.3 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.11.4 Abbvie Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.11.5 Abbvie Recent Developments
11.12 AbCellera
11.12.1 AbCellera Company Details
11.12.2 AbCellera Business Overview
11.12.3 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.12.4 AbCellera Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.12.5 AbCellera Recent Developments
11.13 ABL Bio
11.13.1 ABL Bio Company Details
11.13.2 ABL Bio Business Overview
11.13.3 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.13.4 ABL Bio Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.13.5 ABL Bio Recent Developments
11.14 Abpro
11.14.1 Abpro Company Details
11.14.2 Abpro Business Overview
11.14.3 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.14.4 Abpro Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.14.5 Abpro Recent Developments
11.15 Academy of Military Medical Sciences (China)
11.15.1 Academy of Military Medical Sciences (China) Company Details
11.15.2 Academy of Military Medical Sciences (China) Business Overview
11.15.3 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.15.4 Academy of Military Medical Sciences (China) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.15.5 Academy of Military Medical Sciences (China) Recent Developments
11.16 Accellix
11.16.1 Accellix Company Details
11.16.2 Accellix Business Overview
11.16.3 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.16.4 Accellix Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.16.5 Accellix Recent Developments
11.17 Accord Healthcare
11.17.1 Accord Healthcare Company Details
11.17.2 Accord Healthcare Business Overview
11.17.3 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.17.4 Accord Healthcare Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.17.5 Accord Healthcare Recent Developments
11.18 AccuGenomics
11.18.1 AccuGenomics Company Details
11.18.2 AccuGenomics Business Overview
11.18.3 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.18.4 AccuGenomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.18.5 AccuGenomics Recent Developments
11.19 ACEA Biosciences
11.19.1 ACEA Biosciences Company Details
11.19.2 ACEA Biosciences Business Overview
11.19.3 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.19.4 ACEA Biosciences Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.19.5 ACEA Biosciences Recent Developments
11.20 AC Immune
11.20.1 AC Immune Company Details
11.20.2 AC Immune Business Overview
11.20.3 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.20.4 AC Immune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.20.5 AC Immune Recent Developments
11.21 Acoustic MedSystems
11.21.1 Acoustic MedSystems Company Details
11.21.2 Acoustic MedSystems Business Overview
11.21.3 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.21.4 Acoustic MedSystems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.21.5 Acoustic MedSystems Recent Developments
11.22 Adaptimmune
11.22.1 Adaptimmune Company Details
11.22.2 Adaptimmune Business Overview
11.22.3 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.22.4 Adaptimmune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.22.5 Adaptimmune Recent Developments
11.23 Aduro BioTech
11.23.1 Aduro BioTech Company Details
11.23.2 Aduro BioTech Business Overview
11.23.3 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.23.4 Aduro BioTech Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.23.5 Aduro BioTech Recent Developments
11.24 Advaxis
11.24.1 Advaxis Company Details
11.24.2 Advaxis Business Overview
11.24.3 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.24.4 Advaxis Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.24.5 Advaxis Recent Developments
11.25 Adventus Ventures
11.25.1 Adventus Ventures Company Details
11.25.2 Adventus Ventures Business Overview
11.25.3 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.25.4 Adventus Ventures Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.25.5 Adventus Ventures Recent Developments
11.26 Aerolase
11.26.1 Aerolase Company Details
11.26.2 Aerolase Business Overview
11.26.3 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.26.4 Aerolase Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2017-2022)
11.26.5 Aerolase Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer